Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents

Author： Hartman George D   Fraley Mark E   Bilodeau Mark T  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.11, Iss.6, 2002-06, pp. : 737-745

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development of Vascular Endothelial Growth Factor Receptor (VEGFR) Kinase Inhibitors as Anti-Angiogenic Agents in Cancer Therapy

By  

Current Medicinal Chemistry, Vol. 11, Iss. 6, 2004-03 ,pp. : 731-745

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect

By  

Current Medicinal Chemistry, Vol. 23, Iss. 10, 2016-03 ,pp. : 1000-1040

Bentham Science Publishers

Access to resources Recommend Favorite

VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future

By  

Current Cancer Drug Targets, Vol. 11, Iss. 5, 2011-01 ,pp. : 624-653

Bentham Science Publishers

Access to resources Recommend Favorite

Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents

By  

Mini Reviews in Medicinal Chemistry, Vol. 9, Iss. 4, 2009-04 ,pp. : 498-509

Bentham Science Publishers

Access to resources Recommend Favorite

p38 MAP Kinase Inhibitors as Anti inflammatory Agents

By  

Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 14, 2013-12 ,pp. : 2082-2096

Bentham Science Publishers

Access to resources Recommend Favorite